The Scientist

» innovation and disease/medicine

Most Recent

image: Freezing Time

Freezing Time

By | May 1, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

15 Comments

image: Telomeres in Disease

Telomeres in Disease

By | May 1, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

16 Comments

image: Mad Cow in California

Mad Cow in California

By | April 30, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

0 Comments

image: Amgen Founder Dies

Amgen Founder Dies

By | April 25, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

2 Comments

image: Dangers of Disclosure

Dangers of Disclosure

By | April 25, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

10 Comments

image: Publish H5N1 Papers, Says US Gov’t

Publish H5N1 Papers, Says US Gov’t

By | April 23, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

0 Comments

image: Opinion: A TB Vaccine Blueprint

Opinion: A TB Vaccine Blueprint

By | April 23, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

0 Comments

image: Jumping Gene Linked to MRSA Spread

Jumping Gene Linked to MRSA Spread

By | April 23, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

0 Comments

image: White House Weighs in on H5N1

White House Weighs in on H5N1

By | April 18, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

0 Comments

image: H5N1 Researcher to Defy Dutch Gov’t?

H5N1 Researcher to Defy Dutch Gov’t?

By | April 18, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

4 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech